mesothelioma
Oncology · 2005–2024
9decisions
3medicines
5carried consumer input
5individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab and ipilimumab First-line treatment of patients with unresectable malignant pleural mesothelioma. | Jul 2024 | Not recommended | input received Lung Foundation |
| pemetrexed Patients with malignant pleural mesothelioma or locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. | Mar 2023 | Recommended with restriction | input received Lung Foundation Australia |
| nivolumab and ipilimumab First-line treatment of patients with unresectable malignant pleural mesothelioma (MPM). | Mar 2021 | Recommended with restriction | 5 individuals Asbestos Victims Association · Asbestos Council · Asbestos Diseases Research Institute · Lung Foundation Australia · Asbestos Diseases Society · Rare Cancers Australia · Medical Oncology Group |
| pemetrexed Treatment of patients with malignant pleural mesothelioma in combination with cisplatin; initial treatment of locally advanced or metastatic non-small cell… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pemetrexed Treatment of locally advanced or metastatic non-small cell lung cancer (after prior platinum-based chemotherapy) and malignant pleural mesothelioma (in… | Mar 2016 | Recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| pemetrexed Use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma. Also indicated for the treatment of locally advanced or… | Nov 2007 | Recommended with restriction | no section in document |
| pemetrexed disodium Treatment of patients with malignant pleural mesothelioma in combination with cisplatin. | Nov 2007 | Recommended with restriction | no section in document |
| pemetrexed disodium in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma; and for the treatment of patients with un-resectable locally… | Nov 2005 | Recommended | no section in document |
| pemetrexed disodium In combination with cisplatin for the treatment of patients with malignant pleural mesothelioma (MPM), specifically un-resectable locally advanced or… | Nov 2005 | Recommended | no section in document |
Who spoke
Lung Foundation Australia · Lung Cancer Foundation Australia · Asbestos Victims Association · Asbestos Council · Asbestos Diseases Research Institute · Asbestos Diseases Society · Rare Cancers Australia · Medical Oncology Group · Lung Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.